Table 2.

Third-line treatment per study arm

	DC (%)	D (%)	p-value
No treatment	27 (40.3%)	34 (52.3%)	0.222
Chemotherapy	28 (41.8%)	28 (43.1%)	0.999
EGFR-TKIs*	12 (17.9%)	3 (4.6%)	0.026

*Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor